Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Moleculin Biotech, Inc.

NASDAQ: MBRX · Life Sciences · 16 alerts · CIK 1659617

Share price
$7.14Close, Nov 16
Market cap
$7.58M
Shares outstanding
1.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Moleculin Biotech, Inc. filings on SEC EDGAR ↗

7:31 AM ET 8-K
Financial Results

Moleculin Biotech Financial Results

Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.

“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
4:34 PM ET 10-Q
Financial Results

Moleculin Biotech Q3 2026 Results: Net Loss of $6.49M, Loss Narrows

Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.

Key figure
Net loss $6.49M
8:38 AM ET 8-K
Business Update

Moleculin Biotech Business Update

Moleculin Biotech announced the grant of Australian Patent No. 2020303572, which covers the preparation of preliposomal Annamycin lyophilizate. The patent was granted jointly to Moleculin and The Board of Regents of The University of Texas System, strengthening the company's international intellectual property portfolio for its lead drug candidate, Annamycin.

Counterparty
The Board of Regents of The University of Texas System
4:09 PM ET 8-K
Clinical Trial Data

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.

Counterparty
The University of Texas MD Anderson Cancer Center

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.